このページの翻訳は実験的なもので、現在開発中です。お待ちしております
SAB Biotherapeutics マネジメント
マネジメント 基準チェック /44
SAB Biotherapeutics'の CEO はSamuel Reichで、 Jan2024年に任命され、 の在任期間は 1 年未満です。 の年間総報酬は$ 768.40Kで、 45.5%給与と54.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.24%を直接所有しており、その価値は$ 71.18K 。経営陣と取締役会の平均在任期間はそれぞれ2年と4年です。
主要情報
Samuel Reich
最高経営責任者
US$768.4k
報酬総額
| CEO給与比率 | 45.5% |
| CEO在任期間 | less than a year |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 2.3yrs |
| 取締役会の平均在任期間 | 4.3yrs |
経営陣の近況
Recent updates
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely
Sep 22
Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified
Apr 17Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week
Jan 20Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues
Nov 19Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Nov 18SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial
Sep 28What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates
Aug 12SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03
Aug 10Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term
Apr 06SAB Biotherapeutics: Advancing A New Class Of Immunotherapies Leveraging Polyclonal Antibodies
Dec 02CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$40m |
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$768k | US$350k | -US$42m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$27m |
| Dec 31 2022 | US$985k | US$350k | -US$19m |
| Sep 30 2022 | n/a | n/a | -US$22m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$18m |
| Dec 31 2021 | US$3m | US$53k | -US$17m |
報酬と市場: Samuelの 総報酬 ($USD 768.40K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Samuelの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Samuel Reich (49 yo)
less than a year
在職期間
US$768,396
報酬
Mr. Samuel J. Reich is CEO of SAB Biotherapeutics, Inc. from January 30, 2024 and serves as its Executive Chairman since October 22, 2021 and serves as its Director since November 2020. Samuel J. Reich has...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Chairman | less than a year | US$768.40k | 0.24% $ 56.3k | |
| Co-Founder | 10.7yrs | US$807.76k | 5.67% $ 1.3m | |
| Co-Founder & Independent Director | no data | US$25.00k | 5.63% $ 1.3m | |
| Executive VP & COO | 2.3yrs | US$549.32k | 1.08% $ 256.3k | |
| Executive VP & Chief Medical Officer | 2.3yrs | US$921.58k | 0% $ 0 | |
| Co-Founder & Board Observer | no data | データなし | 3.15% $ 747.6k | |
| Interim Chief Financial Officer | less than a year | データなし | データなし | |
| Senior Vice President of Regulatory Affairs | 3.3yrs | データなし | データなし |
2.3yrs
平均在職期間
53yo
平均年齢
経験豊富な経営陣: SABSの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Chairman | 3.8yrs | US$768.40k | 0.24% $ 56.3k | |
| Co-Founder | no data | US$807.76k | 5.67% $ 1.3m | |
| Co-Founder & Independent Director | 10.7yrs | US$25.00k | 5.63% $ 1.3m | |
| Co-Founder & Board Observer | 2.9yrs | データなし | 3.15% $ 747.6k | |
| Independent Director | 5.7yrs | US$25.00k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$25.00k | 0.43% $ 101.5k | |
| Independent Vice Chairman | 6.7yrs | US$25.00k | 0.062% $ 14.7k | |
| Independent Director | 1.4yrs | US$26.93k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of the Clinical Advisory Board & Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board & Member of Clinical Advisory Board | 4.7yrs | データなし | データなし |
4.3yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: SABSの 取締役会 は 経験豊富 であると考えられます ( 4年の平均在任期間)。